Most lung cancer patients are unfortunately uncurable and die because of widespread metastases, thus indicating the importance of identi®cation of molecules with a crucial role in this process. Our previous expression pro®ling analysis of a highly metastatic lung cancer cell line, NCI-H460-LNM35, and its parental low metastatic line, NCI-H460-N15, revealed signi®cant up-regulation of both known and unknown genes in LNM35. In this study, we describe the isolation and detailed characterizations of a novel gene, named CLCP1, which corresponds to one of such expression sequence tags with up-regulated expression in LNM35. The CLCP1 gene was found to encode a protein with 775 amino acids with structural similarities to, but distinct from neuropilins, cell surface receptors for VEGF 165 and semaphorins. Notably, CLCP1 was shown to be upregulated not only in LNM35 in association with its acquisition of metastatic phenotype during in vivo selection, but also in a signi®cant fraction of lung cancers in vivo with high frequency in metastatic lesions, warranting future studies for a better understanding of the molecular mechanisms of lung cancer metastasis.
Introduction
Lung cancer claims a great number of lives as the number one cause of cancer death in many economically developed nations including Japan, in which more than 50 000 lung cancer deaths are being recorded annually (Statistics and Information Department, Minister's Secretariat, 1999) . Unfortunately, despite considerable advances in the understanding of the molecular carcinogenesis of lung cancer, most patients diagnosed as having this disease eventually die because of widespread metastases (Sekido et al., 2001) . It is therefore of the utmost importance to clarify how lung cancer cells propagate distant metastasis so that the number of lung cancer deaths may be reduced by translating the resultant discoveries into clinical applications.
Tumor metastasis involves a series of complex processes: detachment of tumor cells from the primary tumor mass, microinvasion into stromal tissues, intravasation into and extravasation from the lymphatic or blood vessels and growth in secondary sites (Liotta and Kohn, 2001; Stetler-Stevenson and Kleiner, 2001; Fidler et al., 2001) . To date, various molecules have been suggested as playing a role in these processes, but it is also evident that we still need to learn more about how cancer cells metastasize to distant organs. To propel studies on the molecular mechanisms of lung cancer metastasis, we have established a highly metastatic human lung cancer cell line, NCI-H460-LNM35 (hereafter referred to as LNM35), which is capable of spontaneous metastasis, not only via hematogenous but also lymphogenous routes, with a 100% incidence (Kozaki et al., 2000) . Our subsequent expression pro®ling analysis of LNM35 and a representative low metastatic clone (NCI-H460-N15, hereafter referred to as N15) of NCI-H460, a parental line of LNM35, identi®ed genes upregulated in LNM35 during its in vivo selection (Kozaki et al., 2001) . It is conceivable that upregulation of the identi®ed genes, which include various known genes such as in¯ammatory cytokines and chemokines as well as novel ones represented by ESTs, may contribute to the acquisition of the highly metastatic phenotype of LNM35.
In this report, we describe the isolation and detailed characterizations of a novel gene, named CLCP1, which corresponds to one of the expression sequence tags (ESTs) with up-regulated expression in LNM35. The CLCP1 gene was found to encode a protein with 775 amino acids with structural similarities to, but distinct from neuropilins, cell surface receptors for VEGF 165 and semaphorins. Interestingly, the CLCP1 gene was found to be up-regulated not only in the highly metastatic LNM35 but also in a signi®cant Oncogene (2002 Oncogene ( ) 21, 2822 Oncogene ( ± 2828 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc *Correspondence: T Takahashi; E-mail: tak@aichi-cc.jpfraction of lung cancer cases, especially in lymph node metastasis.
Results
Cloning of full-length cDNA of CLCP1 and the characterization of its genomic structure
We searched for overlapping EST contigs using an EST clone (D29810) as an informative starting point, which was previously identi®ed to be up-regulated in LNM35 in association with the acquisition of metastatic phenotype during its in vivo selection (Kozaki et al., 2001) . Overlapping ESTs were subsequently searched in silico in the NCBI dbEST database by using BLAST, which yielded 50 EST clones. Since the predicted nucleotide sequence did not appear to cover the entire coding region, we also employed the GENSCAN exon prediction program using sequence data of NT 005527.6, which corresponds to ESTs covering most 5' and 3' ends of the transcript, and con®rmed the results by RT ± PCRbased exon connection analysis. In addition, further search for ESTs were carried out in combination with 3' RACE. As a result, three distinct 3' ends of the transcripts were identi®ed, corresponding to the three poly(A + ) addition sites in the 3' non-coding region, which enabled us to clone the full-length cDNAs of 4279, 5893 and 6092 bp, encoding 775 amino acids ( Figure 1A) . Analysis of the deduced amino acids with the aid of the SMART (Simple Modular Architecture Research Tool) domain prediction program revealed its unique domain structure ( Figure 1B ). On the basis of the presence of the CUB, LCCL-homology and coagulation factor V/VIII-homology domains in its extracellular region, we named this gene CLCP1 (CUB, LCCL-homology, coagulation factor V/VIIIhomology domains protein 1). The domain structure of CLCP1 showed signi®cant similarities to, but also distinctions from neuropilins, which are known to serve as a cell surface receptor for VEGF 165 and semaphorins (He and Tessier-Lavigne, 1997; Kolodkin et al., 1997; Soker et al., 1998) . Unlike neuropilins, which contain two each of the CUB and coagulation factor V/VIII-homology domains (Fujisawa and Kitsukawa, 1998; , CLCP1 was composed of one of each. Furthermore, CLCP1 was also distinct from neuropilins in that an insertion of the LCCL domain between the CUB and coagulation factor V/VIII-homology domains was present in CLCP1, whereas the MAM domain present in neuropilins was lacking in the CLCP1 protein . We also used BLAST to determine the genomic structures of the CLCP1 gene by comparing the obtained cDNA sequence and the draft sequence of the human genome (NT 005527.6), ®nding that the CLCP1 gene consists of 16 exons spanning an at least 104 kb genomic region. Nucleotide sequences of the exon ± intron boundaries are shown in Figure 1C .
Expression of CLCP1 in fetal and adult normal tissues
Expression of CLCP1 in human fetal and adult normal tissues was examined by Northern blot analysis ( Figure  2 ). Ubiquitous expression of CLCP1 transcripts 6.5 and 4.5 kb in size was observed in both fetal and adult tissues with the most abundant expression in adult testis. CLCP1 expression was also fairly abundant in skeletal muscle, placenta, heart, colon, ovary and prostate, indicating that the expression pattern of CLCP1 is more similar to that of neuropilin 1 than of neuropilin 2, which is, for example, not expressed in heart (Soker et al., 1998; Chen et al., 1997) .
Up-regulation of CLCP1 in the highly metastatic LNM35 cell line as well as in a significant fraction of lung cancer tissues in vivo Up-regulated expression of CLCP1 in the highly metastatic LNM35 line was con®rmed by Northern blot analysis. In accordance with our previous microarray analysis data, CLCP1 expression level in LNM35 was 7.9-fold higher than that in the low metastatic N15 line ( Figure 3A ). In addition, the low metastatic revertant lines of LNM35, NCI-H460-L2D3A showed signi®cantly lower expression of CLCP1 than LNM35, showing down-regulation of CLCP1 during the selection process of the revertants of LNM35 (data not shown). We also examined 57 primary lung cancer specimens, including 39 primary tumors and 18 metastatic sites, which had been collected from 44 primary lung cancer cases representing all four major histological subtypes, for CLCP1 expression in vivo. CLCP1 expression was identi®ed in 21 (48%) of the 44 lung cancer cases in any of their tumor sites at signi®cantly higher levels than that in adult normal lung ( Figures 3B,C) , while increased CLCP1 expression was observed in 58% (seven of 12) of SCLC as well as in 44% (14 of 32) of NSCLC cases, respectively. As for tumor sites from which these specimens originated, 14 (36%) of the 39 primary sites exhibited increased expression of CLCP1, while increased CLCP1 expression was present in seven (58%) of 12 regional lymph node metastases and two (33%) of six distant metastases ( Figure 3D ).
Characterizations of the CLCP1 protein by transient transfection
Transient transfection of HA-tagged full-length cDNA of CLCP1 was performed to study the CLCP1 protein.
Western blot analysis using anti-HA antibody showed expression of the 100 kD CLCP1 protein (Figure 4a ). It is possible that posttranslational modi®cations such as glycosylation may account for its slightly larger size than that predicted from the deduced amino acid sequence. In this connection, the deduced amino acid sequence of CLCP1 indicated that there are ®ve potential N-glycosylation sites ( Figure 1A ).
An immuno¯uorescent study was also performed to investigate subcellular localization of the CLCP1 Figure 4B ).
Discussion
In this study we cloned and characterized a novel gene, CLCP1, whose corresponding EST was initially identi®ed in our expression pro®ling analysis of highly metastatic LNM35 and its low metastatic parental N15. While CLCP1 expression was con®rmed by Northern blot analysis to be up-regulated during in vivo selection of LNM35, frequent occurrence of increased CLCP1 expression was identi®ed in a signi®cant fraction of human lung cancer cases in vivo, especially in their lymphogenous metastatic sites. In fact, our results indicated that increased CLCP1 expression was present in 36% of primary sites, in 58% of lymph node metastases and in 33% of distant metastases. These ®ndings suggest that increased expression of CLCP1 may be acquired in lung cancers during the process of tumor progression, possibly in relation to the acquisition of metastatic capability. Our previous expression pro®ling analysis of LNM35 and N15 suggested potential eects of an increase in expression of various in¯ammation-related molecules in the acquisition of the highly metastatic capability of LNM35 as well as possible mimicry of in®ltrating in¯ammatory cells in the process of lung cancer metastasis (Kozaki et al., 2001) . However, such activation of in¯ammatory signaling also appeared to be insucient, at least in our system, for full acquisition of the in vitro invasive and possibly in vivo metastatic phenotypes, suggesting that activation of an additional signaling pathway(s) may have been acquired during the in vivo selection of LNM35. Our preliminary result indicates that CLCP1 expression is Figure 2 Detection of CLCP1 transcripts by Northern blot analysis in various fetal and adult tissues. Expressions of CLCP1 transcripts 6.5 and 4.5 kb in size are present rather ubiquitously in both fetal (A) and adult (B) tissues, the highest CLCP1 expression being detectable in adult testis. Ethidium bromide staining of 28S served as a control for RNA loading in the Northern blot of fetal tissue RNAs. MTN TM blots containing 2 mg each of poly(A) + RNA (Clontech) were used for the analysis of CLCP1 expression in adult tissues Oncogene Up-regulation of a novel gene, CLCP1, in lung cancer K Koshikawa et al not inducible in N15 by IL-1b, the expression of which has been shown to be up-regulated in LNM35. This suggests that the latter's non-in¯ammatory signaling pathway may be involved in the up-regulation of CLCP1 (unpublished observation).
Our study clearly shows that in terms of its domain structure, the CLCP1 protein is similar to, but also uniquely dierent from neuropilins, which are known to serve as a cell surface receptor for VEGF 165 and semaphorins (He and Tessier-Lavigne, 1997; Kolodkin et al., 1997; Soker et al., 1998) . Accumulating evidence suggests that VEGF may play a role as an autocrine growth factor mediating motility, invasion, and survival of cancer cells themselves in addition to its paracrine eects on tumor angiogenesis (Bachelder et al., 2001; Hayashibara et al., 2001; Masood et al., 2001; Neufeld et al., 1999; Soker et al., 2001; Veikkola et al., 2000) . Semaphorins, which were originally identi®ed as repulsive molecules for nerve growth cones (Kolodkin et al., 1993; Luo et al., 1993) , are now regarded as having both repulsive and attractant properties (Bagnard et al., 1998) , while there is accumulating evidence that they may also have other functions (Behar et al., 1996) . Notably, it was recently shown that introduction of the neuropilin 1 gene into rat prostate carcinoma cells promotes angiogenesis, leading to enhanced tumor growth . All of the CUB, LCCL and coagulation factor V/VIIIhomology domains, which are present in CLCP1, are believed to participate in ligand binding in various proteins with these features (Bork and Beckmann, 1993; Springer et al., 1984; Trexler et al., 2000) , suggesting that CLCP1 may also be a receptor for a similar and/or distinst ligand(s). Although the precise function of CLCP1 is still elusive, its frequent upregulation in lung cancer metastasis as well as its structural similarity to neuropilins lead us to speculate that this novel gene may play a role during formative events in lung cancer metastasis. Further investigations of its biochemical and biological functions should therefore be of interest, and aim to clarify how it may participate in lung cancer metastasis.
In conclusion, we have cloned a novel gene CLCP1, on the basis of the ®nding of signi®cant up-regulation of the corresponding EST in our expression pro®ling analysis. CLCP1 was shown to be up-regulated not only in LNM35 in association with the acquisition of the metastatic phenotype during in vivo selection but also in a signi®cant fraction of lung cancers in vivo with a notably high frequency in metastatic lesions. Taken together, these ®ndings warrant future studies of this novel gene to better understand the molecular mechanisms of lung cancer metastasis, in the hope that it may ultimately provide a clue as to how to reduce the present, extremely large number of lung cancer deaths.
Materials and methods

Cell lines and lung cancer tissues
Establishment of LNM35, a highly metastatic subline of the NCI-H460 human large cell lung cancer cell line and that of its representative parental (N15) subline have been reported previously (Kozaki et al., 2000) . All cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. Tumor samples together with uninvolved lung tissues were collected from patients diagnosed histologically as having primary lung cancers (12 cases of SCLC, 13 cases of adenocarcinoma, 12 cases of squamous cell carcinoma, and seven cases of large cell carcinoma). All tissues were quickly frozen in liquid nitrogen and stored at 7808C until analysis.
cDNA cloning and characterization of genomic structure Overlapping EST clones were searched for in the dbEST database by using the BLAST program together with an exon prediction program, GENSCAN, to entirely cover the transcribed region. 3'-RACE was carried out to con®rm the 3' ends of the gene essentially as described by Frohman (1993) , using the forward primers, 5'-CCACAAAGCTGTG-GAAGGTG and 5'-CTGGCTCTGCATTGTCACCT, for the ®rst and second round PCR together with a reverse primer 5'-CACGCGTCGTCTAGTACGAC(T) 17 .
Northern blot analysis
Extraction of RNA from cell lines and tissues as well as Northern blot analysis using 10 mg each of the extracted total RNAs were conducted according to the standard procedures, followed by visualization and measurement by means of BAS5000 (Fuji Film Co. Ltd., Tokyo, Japan). Northern blots of various human adult tissues were purchased from Clontech (MTN TM blots, Palo Alto, CA, USA) and analysed according to the manufacturer's instructions. A CLCP1 cDNA probe was generated by polymerase chain reaction with the aid of a sense primer, 5'-CCTTCTCCATGCCTCTGTTC and an antisense primer, 5'-CATGGCAATTTTCTGCTGCC. A full-length CLCP1 cDNA covering the entire coding region was generated by polymerase chain reaction (PCR) with the oligonucleotide primers CLCP1S (sense), 5'-CCCAAG-CTTTGCAGGCAGACTGCCGGC and CLCP1AS (antisense), 5'-CGAGGTACCAAGGATTTCTTTAAAAACAT-CACAT as well as RNAs extracted from a normal lung tissue. The resultant PCR products were cloned into pBSSKII (Stratagene, La Jolla, CA, USA) and sequenced thoroughly. The C-terminally HA-tagged CLCP1 expression vector was constructed by inserting the HindIII/KpnI digested cDNA into the HindIII and KpnI sites of pcDNA3-HA (kindly provided by Dr N Inohara, University of Michigan Medical School). The expression construct (or an empty vector) was transfected into A549 cells using DMRIE-C (Invitrogen Co., Carlsbad, CA, USA). For Western blot analysis, pIRES-puro (Clontech Laboratories, Inc., Palo Alto, CA, USA) was co-transfected and puromycin (2 mg/ ml) was added 24 h after transfection. After a further 24 h of incubation, transfected cells were harvested for analysis.
Western blot and immunofluorescent analyses
Ten micrograms of total cell lysate solubilized in the SDS sample buer (100 mM Tris-HCl pH 8.8, 0.01% bromophenol blue, 25% glycerol, 4% SDS) containing 0.7 mM bmercaptoethanol was electrophoresed on a 10% SDSpolyacrylamide gel and transferred to an Immobilon-P membrane (Millipore Co., Bedford, MA, USA). The ®lter was ®rst incubated with anti-HA polyclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and then with horseradish peroxidase-conjugated secondary antibody (Amersham Life Science, Buckinghamshire, UK). For visualization, an enhanced chemiluminescence system (Amersham) was used.
Immuno¯uorescent staining was performed with the same anti-HA polyclonal antibody as was used for Western blot analysis, while Alexa Fluor dye-labeled secondary antibody (Molecular Probes Inc., Eugene, OR, USA) was used for visualization under a laser scanning confocal microscope (Olympus, Tokyo, Japan).
Note added in proof While this paper was being edited, a cDNA sequence with an identical coding capacity (named ESDN) became available in the GenBank database under the accession number of AF387547.
